Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks

Arnaud Bayle; Antoine Hollebecque; Barbara Pistilli; Christophe Massard; Aurélien Marabelle

doi:10.1016/j.ejca.2021.06.044

Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks

Arnaud Bayle, Antoine Hollebecque, Barbara Pistilli, Christophe Massard, Aurélien Marabelle

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	217-221
Nombre de pages	5
journal	European Journal of Cancer
Volume	156
Les DOIs	https://doi.org/10.1016/j.ejca.2021.06.044
état	Publié - 1 oct. 2021

Accès au document

10.1016/j.ejca.2021.06.044

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Bayle, A., Hollebecque, A., Pistilli, B., Massard, C., & Marabelle, A. (2021). Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks. European Journal of Cancer, 156, 217-221. https://doi.org/10.1016/j.ejca.2021.06.044

Bayle, Arnaud ; Hollebecque, Antoine ; Pistilli, Barbara et al. / Re : Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks. Dans: European Journal of Cancer. 2021 ; Vol 156. p. 217-221.

@article{659104c9ba364881be8529cc3df7a1cf,

title = "Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks",

author = "Arnaud Bayle and Antoine Hollebecque and Barbara Pistilli and Christophe Massard and Aur{\'e}lien Marabelle",

note = "Funding Information: Research Grants from AstraZeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi.",

year = "2021",

month = oct,

day = "1",

doi = "10.1016/j.ejca.2021.06.044",

language = "English",

volume = "156",

pages = "217--221",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Bayle, A, Hollebecque, A, Pistilli, B, Massard, C & Marabelle, A 2021, 'Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks', European Journal of Cancer, VOL. 156, p. 217-221. https://doi.org/10.1016/j.ejca.2021.06.044

Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks. / Bayle, Arnaud; Hollebecque, Antoine; Pistilli, Barbara et al.
Dans: European Journal of Cancer, Vol 156, 01.10.2021, p. 217-221.

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

TY - JOUR

T1 - Re

T2 - Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks

AU - Bayle, Arnaud

AU - Hollebecque, Antoine

AU - Pistilli, Barbara

AU - Massard, Christophe

AU - Marabelle, Aurélien

N1 - Funding Information: Research Grants from AstraZeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi.

PY - 2021/10/1

Y1 - 2021/10/1

UR - http://www.scopus.com/inward/record.url?scp=85115217387&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2021.06.044

DO - 10.1016/j.ejca.2021.06.044

M3 - Letter

C2 - 34400059

AN - SCOPUS:85115217387

SN - 0959-8049

VL - 156

SP - 217

EP - 221

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Bayle A, Hollebecque A, Pistilli B, Massard C, Marabelle A. Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks. European Journal of Cancer. 2021 oct. 1;156:217-221. doi: 10.1016/j.ejca.2021.06.044